USFDA completed an audit of Zydus Lifesciences’ UK subsidiary LiqMeds, issuing 4 procedural Form 483 observations. The company confirmed it will work closely with the regulator to address the observations expeditiously.
Zydus Lifesciences LiqMeds UK Facility Issued 4 Form 483 Observations By USFDA
calendar_today
November 14, 2026
domain
sahi